SCHEMBL4830385

SCHEMBL4830385

NC(=S)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.52
NPFFR2 Q9Y5X5 2/20 0.50
PHGDH O43175 1/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
HDAC3 O15379 2/20 0.46
HDAC4 P56524 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC7 Q8WUI4 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC10 Q969S8 2/20 0.46
HDAC11 Q96DB2 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC9 Q9UKV0 2/20 0.46
HDAC5 Q9UQL6 2/20 0.46
BCAT2 O15382 1/20 0.46
NPFFR1 Q9GZQ6 1/20 0.46
SRD5A2 P31213 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19523347 0.82 SMN1; SMN2 (0.53) TSHRHTTSMN1; SMN2
SCHEMBL7846469 0.80 KCNQ3 (0.41) NPFFR2GLAGAAMAPTHTT
SCHEMBL3374366 0.80 HTT (0.48) MAPTHTTMEN1KMT2ASMN1; SMN2
SCHEMBL20241866 0.80 HTT (0.41) TSHRNPFFR2PHGDHGLAGAA
SCHEMBL10877648 0.79 TSHR (0.55) TSHRNPFFR2MAPTHDAC3HDAC4
SCHEMBL9585784 0.78 TSHR (0.60) TSHRPHGDHSRD5A2
SCHEMBL1838631 0.77 TSHR (0.44) TSHRNPFFR2PHGDHGLAGAA
SCHEMBL1838629 0.77 TSHR (0.44) TSHRNPFFR2PHGDHGLAGAA
SCHEMBL10436207 0.76 LMNA (0.54) TSHRNPFFR2BCAT2NPFFR1SRD5A2
SCHEMBL28866121 0.76 BCAT2 (0.65) TSHRNPFFR2MAPTBCAT2SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020132174-A1 DNA POLYMERASE IIIC INHIBITORS AND USE THEREOF ACURX PHARMACEUTICALS, LLC (US) 2020-06-25 WO disclosed
CN-105753858-A Heterocyclic compound and p27Kip1 degradation inhibitor ASKA制药株式会社 2016-07-13 CN disclosed
CN-102985405-B Heterocyclic compounds and p27Kip1Decomposition inhibitor ASKA制药株式会社 2016-07-06 CN disclosed
US-7439259-B2 Thiazole derivatives for treating PPAR related disorders SMITHKLINE BEECHAM CORPORATION (US) 2008-10-21 US disclosed
US-20060276519-A1 THIAZOLE DERIVATIVES FOR TREATING PPAR RELATED DISORDERS CADILLA RODOLFO 2006-12-07 US disclosed
EP-1343773-B1 THIAZOLE DERIVATIVES FOR TRAEING PPAR RELATED DISORDERS SMITHKLINE BEECHAM CORP (US) 2006-11-02 EP disclosed
US-7105551-B2 Thiazole derivatives for treating PPAR related disorders SMITHKLINE BEECHAM CORPORATION (US) 2006-09-12 US disclosed
US-20040063964-A1 Thiazole derivatives for treating ppar related disorders SMITHKLINE BEECHAM CORPORATION 2004-04-01 US disclosed
US-4431652-A UROGENITAL DISORDERS; KIDNEY AND BLADDER STONES; PROPHYLAXIS; OXIDASE ENZYME INHIBITORS MERCK & CO., INC. (US) 1984-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276519-A1 THIAZOLE DERIVATIVES FOR TREATING PPAR RELATED DISORDERS PPARG, PPARD, PPARA TSHR 251/4885NPFFR2 1354/4885PHGDH 871/4885
US-20040063964-A1 Thiazole derivatives for treating ppar related disorders PPARG, PPARD, PPARA TSHR 232/4885NPFFR2 1288/4885PHGDH 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.